Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Mesenchymal Stem Cells for RA: Can They Calm Inflammation?
Transcript
- 0:00SPEAKER_02: Welcome to the Sirona Cell Podcast.
- 0:02SPEAKER_02: Imagine having a home security system that is um so hypersensitive, it suddenly perceives the drywall of your own house as a deadly intruder.
- 0:12SPEAKER_00: And it just starts tearing down the support beams to get at an enemy that isn't even there.
- 0:16SPEAKER_02: Aaron Ross Powell Yeah.
- 0:17SPEAKER_02: Instead of protecting you, it rips the doors off the hinges.
- 0:20SPEAKER_02: That is the devastating reality of an autoimmune condition.
- 0:24SPEAKER_02: The precision we normally expect in medicine just goes out the window.
- 0:29SPEAKER_00: You are left looking at an incredibly complex chaotic landscape.
- 0:33SPEAKER_02: Aaron Powell So today's mission is to cut through that fog.
- 0:36SPEAKER_02: We are unpacking a massive stack of research, clinical trials, and regulatory guidance to figure out if MSc therapies can actually calm the severe inflammation seen in rheumatoid arthritis.
- 0:48SPEAKER_00: Aaron Powell And uh setting the vocabulary early is important because the medical space around this is currently crowded with incredibly loud, often misleading claims.
- 0:57SPEAKER_02: Got it.
- 0:57SPEAKER_02: And just to set a rule for today, that is the only time I'll be used that full phrase.
- 1:02SPEAKER_02: From here on out, we are strictly going to refer to them as MSCs or simply the cells.
- 1:07SPEAKER_00: Aaron Powell That works.
- 1:08SPEAKER_00: Our goal for this deep dive is a strictly grounded, hype-free exploration of what the scientific literature actually tells us.
- 1:16SPEAKER_02: Aaron Powell I mean, if we look at the central message across all our sources, the takeaway is remarkably clear, isn't it?
- 1:21SPEAKER_00: Aaron Powell It really is.
- 1:22SPEAKER_00: While there is fascinating laboratory research and a handful of small clinical trials showing temporary changes in symptoms, absolutely no trial shows that these cells stop rheumatoid arthritis for good.
- 1:34SPEAKER_02: Aaron Powell We need to unpack that carefully.
- 1:37SPEAKER_02: A temporary change in symptoms is a very long way from a cure.
- 1:41SPEAKER_02: So before we even look at these novel cellular approaches, we have to establish the baseline.
- 1:46SPEAKER_00: We need to understand what rheumatoid arthritis or RA actually is and what the current gold standard of medical care looks like.
- 1:54SPEAKER_02: Because the sheer scope of this disease is staggering.
- 1:57SPEAKER_02: Looking at the World Health Organization data from 2019, 18 million people worldwide were living with RA.
- 2:04SPEAKER_00: Aaron Ross Powell That number represents a tremendous amount of daily disruption.
- 2:08SPEAKER_00: I mean, RA is an autoimmune disorder where your immune system misidentifies the synovium, uh, the delicate lining of your joints, as a foreign threat.
- 2:17SPEAKER_02: Aaron Powell It essentially sends an army of inflammatory cells to attack that lining.
- 2:21SPEAKER_00: Aaron Powell Yeah.
- 2:21SPEAKER_00: And the lining swells up, becomes thick, and starts releasing enzymes.
- 2:25SPEAKER_00: Over time, those enzymes literally chew through the cartilage and erode the bone itself.
- 2:30SPEAKER_02: Aaron Powell Because it is an autoimmune condition, the WHO is very clear that RA is not currently curable, although some people do reach full remission with early aggressive care.
- 2:40SPEAKER_00: Aaron Ross Powell That standard care currently rests on four main pillars of medicine.
- 2:44SPEAKER_02: Aaron Ross Powell I like to think of this like a fire department responding to a multi-alarm house fire.
- 2:49SPEAKER_02: Your first tool is pain relievers.
- 2:51SPEAKER_02: That is the water, cooling the flames and easing the immediate painful swelling.
- 2:55SPEAKER_00: The water is essential, sure.
- 2:56SPEAKER_02: Aaron Ross Powell And then you have steroids, which act like the heavy chemical foam, rapidly suppressing the acute inflammation during a severe flare-up.
- 3:05SPEAKER_00: But water and foam do not stop the fire from spreading to the rest of the house.
- 3:08SPEAKER_00: To do that, you need the third pillar, the disease-modifying drugs, or DMARDs.
- 3:14SPEAKER_02: In your analogy, DMARDs are the emergency team going down into the basement and shutting off the main gas line that is constantly feeding the fire.
- 3:22SPEAKER_02: They actually slow the progression of the disease itself.
- 3:25SPEAKER_00: And finally, we have the biologics.
- 3:27SPEAKER_02: These are highly advanced medications.
- 3:29SPEAKER_02: Instead of just spraying water everywhere, biologics are like technicians intercepting the specific radio signals the fire alarm is sending out.
- 3:38SPEAKER_00: I see the comparison.
- 3:40SPEAKER_00: They block specific inflammatory messengers in the immune system, cutting the wire to the siren without shutting down the power to the entire neighborhood.
- 3:48SPEAKER_02: Which brings us to a massive, non-negotiable rule for this deep dive.
- 3:51SPEAKER_02: Nobody listening to this should ever stop or change their prescribed medicines without their own doctor's advice.
- 3:57SPEAKER_00: Never.
- 3:58SPEAKER_00: Maintaining that baseline of conventional care is critical.
- 4:02SPEAKER_00: Any stem cell approach we talk about today has to be viewed strictly as a potential adjunct to conventional care.
- 4:08SPEAKER_02: It is not a replacement.
- 4:09SPEAKER_02: You don't fire the fire department just because someone handed you an experimental fire extinguisher.
- 4:14SPEAKER_00: The reason researchers are even testing these cells in human trials is that biology is messy.
- 4:20SPEAKER_00: A subset of patients simply do not respond to those standard treatments.
- 4:24SPEAKER_02: There are people who fail to see meaningful benefits even after trying multiple advanced biologics.
- 4:29SPEAKER_00: That desperate clinical need drives the search for alternatives.
- 4:33SPEAKER_00: But when we transition from conventional care to the evidence for the cells, we are looking at very small, very early studies.
- 4:41SPEAKER_02: Let's get into the actual evidence then, because the trials paint a complicated picture.
- 4:46SPEAKER_02: I want to look at the three small trials highlighted in the literature, starting with the study from 2019.
- 4:51SPEAKER_00: Okay, that one followed 64 people with RA over a period of three years.
- 4:56SPEAKER_00: These patients were given cells derived from umbilical cord tissue.
- 4:59SPEAKER_02: And the researchers reported lower disease scores at the three-year mark.
- 5:03SPEAKER_02: But reading the methodology, there is a massive red flag here.
- 5:07SPEAKER_02: This study completely lacked a comparison group.
- 5:10SPEAKER_00: Aaron Powell A missing control group in a rheumatoid arthritis trial makes it nearly impossible to draw firm scientific conclusions.
- 5:17SPEAKER_02: I want to break down exactly why that is.
- 5:19SPEAKER_02: Because to a casual reader, lower disease scores for three years sounds like a massive victory.
- 5:24SPEAKER_02: But to me, doing a trial without a control group is like deciding to go on a strict new diet in November to cure your seasonal allergies.
- 5:31SPEAKER_00: Aaron Powell And then feeling better in December and writing a blog post praising the diet.
- 5:35SPEAKER_02: Aaron Powell Yeah.
- 5:35SPEAKER_02: But without a control group, you have no idea if the diet actually worked or if you're experiencing a placebo effect.
- 5:42SPEAKER_02: Or if your allergies just naturally went away because the pollen disappeared when winter arrived.
- 5:46SPEAKER_00: Rheumatoid arthritis behaves very much like those changing seasons.
- 5:50SPEAKER_00: The disease naturally waxes and wanes.
- 5:53SPEAKER_00: Patients go through seasons of severe, debilitating flare-ups, followed by seasons of relative quiet.
- 5:59SPEAKER_00: So if a patient enrolls in a trial during a severe flare-up, statistical regression suggests they are likely to feel somewhat better a few months later simply because the flare naturally subsided.
- 6:10SPEAKER_00: If you don't have a placebo group receiving a dummy saline infusion but getting the exact same level of medical attention, you cannot prove causality.
- 6:28SPEAKER_00: Which brings us to the 2017 trial.
- 6:31SPEAKER_00: That one was a placebo-controlled trial.
- 6:33SPEAKER_00: It involved 53 people with hard-to-treat RA given cells derived from donor fat tissue, and they were followed for 24 weeks.
- 6:41SPEAKER_02: And what did that one show?
- 6:43SPEAKER_02: Since it actually had a control group?
- 6:45SPEAKER_00: Aaron Powell The researchers only observed early hints of benefit.
- 6:48SPEAKER_00: When they looked at the patient's disease scores, the response rates were actually lower at month three than they were at month one.
- 6:55SPEAKER_02: Aaron Powell So the patients experienced an initial dip in their symptoms, but that relief started fading within just a few weeks.
- 7:02SPEAKER_00: Aaron Powell Yes.
- 7:03SPEAKER_00: And that same methodological flaw we saw earlier shows up in the third trial we need to discuss, another study from 2019.
- 7:09SPEAKER_02: Aaron Powell This one was incredibly small, involving just nine people with hard-to-treat RA given cells harvested from their own bone marrow and followed for 12 months.
- 7:19SPEAKER_00: The authors reported lower disease scores at months one and twelve, but once again, there was absolutely no placebo comparison group.
- 7:27SPEAKER_00: Relying on a sample size of nine people without a control group leaves us in a very ambiguous space clinically.
- 7:33SPEAKER_02: If I'm listening to this right now, I'm probably wondering why anyone is still pouring funding into this.
- 7:39SPEAKER_02: If the clinical results in humans are this mixed and frankly, this flawed in their design, why is there still so much momentum behind this research?
- 7:48SPEAKER_00: The persistence of the scientific community comes entirely from what researchers see these cells doing in a petri dish.
- 7:54SPEAKER_00: The laboratory theory behind how these cells interact with the immune system is highly sophisticated.
- 7:59SPEAKER_02: Aaron Powell Let's dive into that laboratory theory.
- 8:03SPEAKER_02: How are these cells supposedly working?
- 8:05SPEAKER_02: And let's be abundantly clear with the listener here, we are strictly talking about laboratory evidence and animal models right now, not human trial results.
- 8:14SPEAKER_00: In the lab, researchers observe that the cells don't just sit there.
- 8:18SPEAKER_00: They actively release specific chemical signals that attempt to rebalance the immune system.
- 8:23SPEAKER_00: They appear to do three critical things.
- 8:25SPEAKER_02: Okay.
- 8:26SPEAKER_02: What is the first?
- 8:27SPEAKER_00: First, they release molecules that possibly raise the levels of regulatory T cells.
- 8:32SPEAKER_00: You can think of regulatory T cells as your immune system's peacekeepers.
- 8:36SPEAKER_00: Their job is to pump the brakes on an immune response.
- 8:40SPEAKER_00: Got it.
- 8:40SPEAKER_02: And the second?
- 8:41SPEAKER_00: Second, the cells seem to lower the levels of TH17 cells.
- 8:45SPEAKER_00: TH17 cells are the aggressive drivers of autoimmune inflammation, secreting proteins that recruit other attack cells to the joint.
- 8:53SPEAKER_02: Aaron Ross Powell So they boost the peacekeepers and suppress the instigators.
- 8:58SPEAKER_02: What is the third thing they do?
- 8:59SPEAKER_00: Aaron Powell The third action involves nudging macrophages out of their inflammatory state.
- 9:03SPEAKER_00: In an actively inflamed RA joint, macrophages are mostly in an aggressive tissue-damaging state.
- 9:09SPEAKER_02: Aaron Ross Powell And the cells change that?
- 9:11SPEAKER_00: Yes.
- 9:11SPEAKER_00: In a laboratory setting, the cells release signals that tell those macrophages to shift into a calming tissue cleanup state.
- 9:18SPEAKER_02: Aaron Powell I love that visual.
- 9:20SPEAKER_02: It's like a highly trained mediator stepping into a heated, chaotic argument.
- 9:25SPEAKER_02: Instead of locking the doors and shutting off the power to the whole building to stop the fight, the mediator steps into the room.
- 9:32SPEAKER_00: They tell the TH-17 instigators to sit down and be quiet.
- 9:36SPEAKER_02: They empower the regulatory T cell peacekeepers to take charge.
- 9:41SPEAKER_00: And they talk the aggressive macrophages off the ledge, convincing them to grab a broom and start cleaning up the mess instead of throwing more chairs.
- 9:48SPEAKER_02: It is a brilliant mechanism when observed in an isolated environment.
- 9:52SPEAKER_02: But here is the crucial caveat that we must emphasize.
- 9:56SPEAKER_02: While the cells might act as mediators for inflammation, repairing eroded cartilage and rebuilding destroyed bone in an RA patient remains purely a laboratory idea.
- 10:06SPEAKER_00: That is a massive distinction.
- 10:09SPEAKER_02: Feeling less pain because the inflammation mediator stepped into the joint is entirely different from regenerating a bone that has already been physically eroded by the disease.
- 10:19SPEAKER_00: The trials we just discussed only measured subjective disease scores and symptoms, not rebuilt joints.
- 10:25SPEAKER_02: Moving from an elegant theory in a pristine laboratory into the messy reality of the human body introduces a host of complicated variables.
- 10:33SPEAKER_02: Not all cells are the same, and the procedure carries risks.
- 10:37SPEAKER_00: Let's break down those cell sources because the three trials we highlighted used three completely different sources.
- 10:43SPEAKER_00: Bone marrow, fat, and umbilical cord cells each have different traits.
- 10:47SPEAKER_02: Why does the origin of the cell matter so much?
- 10:50SPEAKER_00: Because a cell's environment dictates its capabilities.
- 10:53SPEAKER_00: For instance, obtaining cells from bone marrow requires an invasive harvest.
- 10:57SPEAKER_02: And what about the cells derived from fat tissue?
- 11:00SPEAKER_00: Fat-derived cells have shown they have more stable effects in low oxygen environments.
- 11:05SPEAKER_00: Highly inflamed joints usually have very poor microcirculation, meaning they are starved of oxygen.
- 11:10SPEAKER_02: Aaron Powell And the third source, the umbilical cord cells?
- 11:13SPEAKER_00: They grow rapidly in the laboratory and lack certain surface markers, meaning they generally cause less of an immediate immune reaction.
- 11:20SPEAKER_02: Aaron Powell Since we are on the Cyrona Cell podcast, this is the appropriate place to weave in how they actually operate in this space.
- 11:27SPEAKER_02: Cyrona Cell is a regenerative medicine center based in Kuala Lumpur, serving local and international patients, notably from Australia and the Middle East.
- 11:37SPEAKER_00: They state that their specific program uses umbilical cord-derived Wharton's Jelly MSCs.
- 11:44SPEAKER_02: I want to pause there because we need a translation for Wharton's jelly.
- 11:48SPEAKER_02: What is that?
- 11:49SPEAKER_00: Wharton's jelly is the gelatinous protective tissue inside the umbilical cord that shields the blood vessels.
- 11:55SPEAKER_02: Cyrone Cell also states that these cells are processed to BSL2, CGMP, and ISO 9001 standards.
- 12:03SPEAKER_02: Let's translate that alphabet soup as well.
- 12:05SPEAKER_02: BSL2 stands for Biosafety Level 2, meaning strict laboratory containment.
- 12:11SPEAKER_00: CGMP stands for current good manufacturing practice, ensuring batch consistency.
- 12:16SPEAKER_02: And ISO 9001 is an international standard for meticulous quality tracking.
- 12:22SPEAKER_00: But we need to be very clear about how we present that information.
- 12:25SPEAKER_00: Those are the center's own statements.
- 12:28SPEAKER_00: We are presenting them as precisely that, and never as proof of benefit in RA and never as regulatory approval.
- 12:35SPEAKER_00: Furthermore, we do not rank these cell sources or suggest that umbilical cord cells are better than the others.
- 12:41SPEAKER_00: The core scientific takeaway is that because the three major trials use three entirely different sources, results from one product may not carry over to another.
- 12:50SPEAKER_02: Which makes pinning down the safety profile a bit of a moving target.
- 12:53SPEAKER_02: What do we actually know about the risks of infusing these cells?
- 12:57SPEAKER_00: In the small trials we've discussed, the reported side effects were mostly mild.
- 13:01SPEAKER_00: In that 64-person umbilical cord study, about 4% of people experience flu-like symptoms.
- 13:07SPEAKER_00: However, in the placebo-controlled trial using fat cells, there was one serious adverse event reported.
- 13:13SPEAKER_00: A patient suffered a small stroke.
- 13:14SPEAKER_02: Aaron Ross Powell A stroke is a severe life-altering risk.
- 13:17SPEAKER_00: Aaron Powell It is a critical data point.
- 13:20SPEAKER_00: And when we look at a major 2025 review of the field, the authors explicitly name blood clots during the infusion as the main safety concern.
- 13:27SPEAKER_02: Aaron Powell There is another detail in that 2025 review that I have to point out because it feels like a massive contradiction.
- 13:34SPEAKER_02: The review states that the clinical benefit of the cells may fade after about three months.
- 13:40SPEAKER_00: Yes, that is what the review concluded.
- 13:42SPEAKER_02: Aaron Powell But we just discussed the 2019 trial claiming patients had lower disease scores for up to three years.
- 13:48SPEAKER_02: How can an independent review conclude three months when a published trial claims three years?
- 13:53SPEAKER_00: Aaron Powell This brings us right back to the fatal flaw of the 2019 trial, the lack of a placebo group.
- 13:59SPEAKER_00: When independent researchers filter out the noise, they see the most reliable data points to the benefits fading around the three-month mark.
- 14:05SPEAKER_02: Aaron Powell So the actual dose, the schedule of infusions, and the durability remain entirely unknown.
- 14:12SPEAKER_00: Aaron Powell Completely unknown.
- 14:14SPEAKER_02: If I am an RA patient, I am looking at a landscape where the cell types vary wildly, the benefits might fade in 90 days, and there is a real risk of blood clots.
- 14:24SPEAKER_02: How does a patient specifically in Malaysia navigate this responsibly?
- 14:28SPEAKER_00: The first step is understanding the regulatory landscape.
- 14:31SPEAKER_00: In Malaysia, the National Pharmaceutical Regulatory Agency, or NPRA, issued guidance in September 2025.
- 14:37SPEAKER_02: And what does that guidance say?
- 14:39SPEAKER_00: It places cells that laboratories alter and donor cells that act on the whole body into the higher risk class two category.
- 14:47SPEAKER_02: So they are treated with a much higher level of scrutiny.
- 14:50SPEAKER_02: Navigating a class two biologic feels like trying to buy a complex vehicle.
- 14:54SPEAKER_02: You would never hand over your money for a car like that based on the verbal promise.
- 14:58SPEAKER_02: You demand the car facts.
- 15:00SPEAKER_00: You need the technical spec sheet in writing.
- 15:02SPEAKER_00: A patient must ask their provider a series of five very precise questions in writing before any treatment.
- 15:08SPEAKER_00: First, ask how the NPRA classifies the exact product, and which NPRA registration or ethics reviewed trial covers it.
- 15:18SPEAKER_01: What is the second question?
- 15:20SPEAKER_00: Second, ask which published RA study used this exact cell source.
- 15:25SPEAKER_00: Third, ask how each specific batch is tested.
- 15:28SPEAKER_02: And regarding the actual procedure?
- 15:30SPEAKER_00: Fourth, you need to know who the treating doctor is, the written adverse effects, the follow-up plan, and the total cost.
- 15:37SPEAKER_00: And the fifth question is how your own doctor will receive the follow-up results.
- 15:41SPEAKER_02: Just to connect this back to the CironaCell context, they work with partner facilities in Kuala Lumpur where the treating doctors actually give the treatment.
- 15:50SPEAKER_02: So you would use the CironaCell team as your point of contact to explain how those facilities arrange treatment.
- 15:56SPEAKER_00: Regardless of which clinic you use, getting those five points in writing is essential.
- 16:00SPEAKER_02: Let's pull all of this together.
- 16:03SPEAKER_02: What is the grounded core truth we can synthesize from all these sources?
- 16:08SPEAKER_00: The core truth is that the cells may lower disease scores temporarily, according to some small trials, but they are an adjunct to conventional care, not a cure.
- 16:17SPEAKER_02: There is no guaranteed success rate, and there is no standard timeline for results.
- 16:22SPEAKER_00: Exactly.
- 16:23SPEAKER_00: I mean, that is the main takeaway.
- 16:25SPEAKER_02: Which leads to our ultimate call to action for anyone listening today.
- 16:28SPEAKER_02: Talk directly with your own rheumatologist about the latest evidence and realistic goals before making any decisions.
- 16:35SPEAKER_00: Your own doctor understands your specific disease better than anyone else.
- 16:39SPEAKER_02: Before we wrap up this deep dive, I want to leave you with one final thought to mull over.